Department of Dermatology, Gifu Prefectural Tajimi Hospital, Gifu, Japan
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Department of Dermatology, Aichi Medical University, Aichi, Japan
Meguro Chen Dermatology Clinic, Tokyo, Japan
Pazopanib is an oral multi-targeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma. Cutaneous adverse effects of pazopanib are very rare. We herein report a patient with advanced RCC who developed, during chemotherapy with pazopanib, multiple ulcers on both lower legs associated with cutaneous vascular degeneration.
A 66-year-old man was diagnosed with metastatic RCC (of clear cell type) and underwent left nephrectomy. Thereafter, [...]